Advertisement
Screener

Perrigo Company plc (PRGO) Proceeds from Interest Received

2.8 / 5 stars · 68/120 Roast Me

Perrigo Company plc Proceeds from Interest Received

Perrigo Company plc (PRGO) reported Proceeds from Interest Received of $60.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromInterestReceived · last filed 2026-02-26

  • Perrigo Company plc proceeds from interest received for the quarter ending 2016-12-31 was $100.00K, a 75.00% decline year-over-year.
  • Perrigo Company plc proceeds from interest received for the quarter ending 2016-10-01 was $400.00K, a 33.33% increase year-over-year.
  • Perrigo Company plc proceeds from interest received for the quarter ending 2016-07-02 was $300.00K, a 40.00% decline year-over-year.
  • Perrigo Company plc proceeds from interest received for the quarter ending 2016-04-02 was $400.00K, a 100.00% increase year-over-year.
  • Perrigo Company plc proceeds from interest received for fiscal 2025 was $60.40M, a 19.47% decline from fiscal 2024.
  • Perrigo Company plc proceeds from interest received for fiscal 2024 was $75.00M, a 25.60% decline from fiscal 2023.
  • Perrigo Company plc proceeds from interest received for fiscal 2023 was $100.80M, a 73.20% increase from fiscal 2022.
  • Perrigo Company plc proceeds from interest received for fiscal 2022 was $58.20M, a 627.50% increase from fiscal 2021.
Period endProceeds from Interest Received 3 monthProceeds from Interest Received 6 monthProceeds from Interest Received 9 monthProceeds from Interest Received 12 month
2025-12-31$60.40M
10-K · filed 2026-02-26
2024-12-31$75.00M
10-K · filed 2026-02-26
2023-12-31$100.80M
10-K · filed 2026-02-26
2022-12-31$58.20M
10-K · filed 2025-02-28
2021-12-31$8.00M
10-K · filed 2024-02-27
2020-12-31$12.10M
10-K · filed 2023-02-28
2019-12-31$15.10M
10-K · filed 2022-03-01
2018-12-31$5.00M
10-K · filed 2021-03-01
2017-12-31$9.30M
10-K · filed 2020-02-27
2016-12-31$100.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-02-27
$500.00K
derived: sum of 2 quarters · filed 2019-02-27
$800.00K
derived: sum of 3 quarters · filed 2019-02-27
$1.20M
10-K · filed 2019-02-27
2016-10-01$400.00K
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-05-23
$700.00K
derived: sum of 2 quarters · filed 2017-05-23
$1.10M
10-Q/A · filed 2017-05-23
$1.50M
derived: sum of 4 quarters · filed 2018-03-01
2016-07-02$300.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22
$700.00K
10-Q/A · filed 2017-05-22
$1.10M
derived: sum of 3 quarters · filed 2018-03-01
$1.40M
derived: sum of 4 quarters · filed 2018-03-01
2016-04-02$400.00K
10-Q/A · filed 2017-05-22
$800.00K
derived: sum of 2 quarters · filed 2018-03-01
$1.10M
derived: sum of 3 quarters · filed 2018-03-01
$1.60M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31$400.00K
derived: 10-K 6 month − 10-Q 3 month · filed 2018-03-01
$700.00K
10-K · filed 2018-03-01
$1.20M
derived: sum of 3 quarters · filed 2018-03-01
$1.40M
derived: sum of 4 quarters · filed 2018-03-01
2015-09-26$300.00K
10-Q · filed 2015-11-02
$800.00K
derived: sum of 2 quarters · filed 2017-05-22
$1.00M
10-Q/A · filed 2017-05-23
$1.20M
derived: sum of 4 quarters · filed 2017-05-22
2015-06-27$500.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22
$700.00K
10-Q/A · filed 2017-05-22
$900.00K
derived: sum of 3 quarters · filed 2017-05-22
$1.10M
10-K · filed 2018-03-01
2015-03-28$200.00K
10-Q/A · filed 2017-05-22
$400.00K
derived: sum of 2 quarters · filed 2017-05-22
$600.00K
10-Q · filed 2015-04-29
$900.00K
derived: sum of 4 quarters · filed 2017-05-22
2014-12-27$200.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-05
$400.00K
10-Q · filed 2015-02-05
$700.00K
derived: sum of 3 quarters · filed 2017-05-22
$1.20M
derived: sum of 4 quarters · filed 2017-05-22
2014-09-27$200.00K
10-Q · filed 2015-11-02
$500.00K
derived: sum of 2 quarters · filed 2017-05-22
$1.00M
derived: sum of 3 quarters · filed 2017-05-22
$2.40M
derived: sum of 4 quarters · filed 2017-05-22
2014-06-28$300.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22
$800.00K
derived: sum of 2 quarters · filed 2017-05-22
$2.20M
derived: sum of 3 quarters · filed 2017-05-22
$2.40M
10-K · filed 2017-05-22
2014-03-29$500.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29
$1.90M
derived: sum of 2 quarters · filed 2015-04-29
$2.10M
10-Q · filed 2015-04-29
$3.50M
derived: sum of 4 quarters · filed 2016-02-25
2013-12-28$1.40M
derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05
$1.60M
10-Q · filed 2015-02-05
$3.00M
derived: sum of 3 quarters · filed 2016-02-25
$2.80M
derived: sum of 4 quarters · filed 2016-02-25
2013-09-28$200.00K
8-K · filed 2014-11-20
$1.60M
derived: sum of 2 quarters · filed 2016-02-25
$1.40M
derived: sum of 3 quarters · filed 2016-02-25
2013-06-29$1.40M
derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25
$1.20M
derived: sum of 2 quarters · filed 2016-02-25
$3.90M
10-KT · filed 2016-02-25
2013-03-30-$200.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07
$2.50M
10-Q · filed 2014-05-07
2012-12-29$2.70M
10-Q · filed 2014-02-06
2012-06-30$4.00M
10-K · filed 2014-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Generate Biomedicines, Inc. (GENB)United States$2.052B
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38